Published in Cold Spring Harb Perspect Med on April 01, 2012
Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord (2014) 1.63
Gene therapy in Parkinson's disease: targeting the endplasmic reticulum proteostasis network. Neural Regen Res (2015) 1.39
Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease? Front Neuroanat (2016) 1.39
Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther (2013) 1.18
Gene-based therapies in Parkinson's disease. Neurotherapeutics (2014) 0.83
The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting. Lab Invest (2014) 0.82
ER proteostasis disturbances in Parkinson's disease: novel insights. Front Aging Neurosci (2015) 0.78
Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson's Disease. Front Aging Neurosci (2016) 0.77
Design of virus-based nanomaterials for medicine, biotechnology, and energy. Chem Soc Rev (2016) 0.77
There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease. Mol Ther (2014) 0.76
Clinical profile of Parkinson's disease in the Gumei community of Minhang district, Shanghai. Clinics (Sao Paulo) (2014) 0.75
Adeno-Associated Viral Vectors Serotype 8 for Cell-Specific Delivery of Therapeutic Genes in the Central Nervous System. Front Neuroanat (2017) 0.75
Enhancing titres of therapeutic viral vectors using the transgene repression in vector production (TRiP) system. Nat Commun (2017) 0.75
Roles of Rheb(S16H) in substantia nigra pars compacta dopaminergic neurons in vivo. Biomed Rep (2014) 0.75
Ret is essential to mediate GDNF's neuroprotective and neuroregenerative effect in a Parkinson disease mouse model. Cell Death Dis (2016) 0.75
Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed? J Neural Transm (Vienna) (2012) 0.75
Current Topics in Deep Brain Stimulation for Parkinson Disease. Neurol Med Chir (Tokyo) (2016) 0.75
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol (2008) 17.81
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell (2009) 13.02
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol (1997) 12.11
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol (1998) 8.21
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet (2000) 7.83
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet (2007) 7.01
GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science (1993) 6.73
Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol (1989) 6.69
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell (2011) 6.56
Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med (1969) 6.16
Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J (1991) 6.13
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med (2003) 4.51
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol (2011) 4.23
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science (2000) 3.89
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol (2000) 2.98
Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci (2008) 2.93
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology (2008) 2.80
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A (2009) 2.61
Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther (2003) 2.49
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther (2006) 2.41
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology (2009) 2.37
Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron (2003) 2.12
Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain (2002) 1.99
Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol (2000) 1.98
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.98
Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther (2001) 1.88
Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature (1995) 1.79
Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol (1999) 1.75
Gene transfer vectors derived from equine infectious anemia virus. Gene Ther (1998) 1.74
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.70
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain (2007) 1.66
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol (2006) 1.66
Recent developments in adeno-associated virus vector technology. J Gene Med (2008) 1.66
In vivo enhancement of tyrosine hydroxylation in rat striatum by tetrahydrobiopterin. Nature (1974) 1.51
Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res (2007) 1.50
Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci (2001) 1.48
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol (2006) 1.46
Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. J Virol (2004) 1.45
Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci (2008) 1.43
Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science (2002) 1.40
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord (2010) 1.39
GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain (2011) 1.38
Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol (2003) 1.34
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain (2002) 1.30
RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res (2007) 1.28
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A (2003) 1.27
Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol (2006) 1.27
In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther (2010) 1.26
Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab (2006) 1.26
Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci U S A (1995) 1.26
Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J Neurosci (2003) 1.25
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem (2002) 1.25
Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med (2009) 1.25
GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res (1995) 1.25
Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol Dis (2004) 1.22
Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther (2009) 1.21
Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res (2009) 1.20
Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther (2000) 1.18
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci (1999) 1.16
Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther (2002) 1.15
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis (2007) 1.15
Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome. PLoS Pathog (2010) 1.12
Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci (2002) 1.10
Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector. Hum Gene Ther (2003) 1.10
DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Mol Ther (2007) 1.08
Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One (2010) 1.08
Emerging restorative treatments for Parkinson's disease. Prog Neurobiol (2008) 1.06
Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther (2007) 1.06
rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Exp Neurol (2007) 1.05
Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum Gene Ther (2005) 1.05
Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci U S A (2002) 1.04
Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther (2009) 1.03
Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci (2000) 1.02
Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol Ther (2006) 0.99
Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates. Neuroscience (2006) 0.97
Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology (2009) 0.96
Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm Park Dis Dement Sect (1994) 0.95
Protection of nigral neurons by GDNF-engineered marrow cell transplantation. Neurosci Res (2001) 0.93
Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem Biophys Res Commun (2006) 0.93
Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. Gene Ther (2005) 0.90
Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp Neurol (2002) 0.90
Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor. Exp Neurol (1999) 0.89
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain (2005) 0.89
GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J Neurosci (1997) 0.89
L-Dopa and dopamine-producing gene cassettes for gene therapy approaches to Parkinson's disease. Exp Neurol (1997) 0.88
Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol Dis (2004) 0.88
Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. J Neurosci (2009) 0.88
Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol Dis (2005) 0.87
A versatile tool for conditional gene expression and knockdown. Nat Methods (2006) 2.92
Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med (2005) 2.80
Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci (2012) 2.35
α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem (2012) 2.31
Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther (2008) 2.14
GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One (2007) 1.99
Lentiviral-mediated RNA interference. Hum Gene Ther (2002) 1.99
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90
GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther (2005) 1.72
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.70
Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther (2008) 1.66
The Kruppel-associated box repressor domain can trigger de novo promoter methylation during mouse early embryogenesis. J Biol Chem (2007) 1.59
Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Curr Biol (2004) 1.55
Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet (2008) 1.49
Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci (2010) 1.46
Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci (2002) 1.40
Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol Pain (2009) 1.39
Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest (2008) 1.38
Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol Dis (2005) 1.37
Behaviour-dependent recruitment of long-range projection neurons in somatosensory cortex. Nature (2013) 1.36
Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci (2005) 1.27
Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol Ther (2007) 1.26
A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci (2011) 1.25
GDNF and NGF released by synthetic guidance channels support sciatic nerve regeneration across a long gap. Eur J Neurosci (2002) 1.25
Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A (2013) 1.24
Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J Neurosci (2008) 1.23
Using human neural stem cells to model neurological disease. Nat Rev Genet (2004) 1.20
GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys. Cell Transplant (2008) 1.19
Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J Neurosci (2006) 1.16
Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. Hum Mol Genet (2007) 1.13
Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Mol Ther (2009) 1.13
Conditional gene expression and knockdown using lentivirus vectors encoding shRNA. Methods Mol Biol (2008) 1.11
Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy. J Neurosci Methods (2007) 1.11
Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proc Natl Acad Sci U S A (2014) 1.11
Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol (2012) 1.10
Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci (2002) 1.10
Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. Hum Mol Genet (2003) 1.10
Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. Mol Ther (2010) 1.07
Lentivirus-mediated expression of glutathione peroxidase: neuroprotection in murine models of Parkinson's disease. Neurobiol Dis (2005) 1.07
Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model. Mol Ther (2013) 1.06
Large-scale chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced pathology and modulates macrophage phenotype following spinal cord contusion injury. J Neurosci (2014) 1.05
Intracerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type-specific transgene expression in the spinal cord. Hum Gene Ther (2014) 1.02
Glial cell line-derived neurotrophic factor released by synthetic guidance channels promotes facial nerve regeneration in the rat. J Neurosci Res (2002) 1.02
Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res (2002) 1.01
Dysregulation of voltage-gated sodium channels by ubiquitin ligase NEDD4-2 in neuropathic pain. J Clin Invest (2013) 0.99
Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J Neurosci (2012) 0.99
Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease. Neurobiol Dis (2009) 0.99
Seizure suppression by adenosine-releasing cells is independent of seizure frequency. Epilepsia (2002) 0.99
Delta-like 1 participates in the specification of ventral midbrain progenitor derived dopaminergic neurons. J Neurochem (2007) 0.98
CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity. J Neurosci (2006) 0.95
Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther (2007) 0.94
Regulation of prenatal human retinal neurosphere growth and cell fate potential by retinal pigment epithelium and Mash1. Stem Cells (2008) 0.93
Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1(G93A) transgenic mice. Neurobiol Dis (2004) 0.92
Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Exp Neurol (2004) 0.92
AAV-mediated expression of wild-type and ALS-linked mutant VAPB selectively triggers death of motoneurons through a Ca2+-dependent ER-associated pathway. J Neurochem (2010) 0.91
Use of viral vectors to create animal models for Parkinson's disease. Neurobiol Dis (2011) 0.91
Collapsin response mediator protein 4a (CRMP4a) is upregulated in motoneurons of mutant SOD1 mice and can trigger motoneuron axonal degeneration and cell death. J Neurosci (2010) 0.91
Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production. J Neurochem (2005) 0.90
PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein. Acta Neuropathol Commun (2015) 0.89
Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol Dis (2004) 0.88
Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles. Hum Gene Ther (2013) 0.88
FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra. Hum Mol Genet (2013) 0.88
Regulation of episomal gene expression by KRAB/KAP1-mediated histone modifications. J Virol (2009) 0.87
Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol Dis (2005) 0.87
Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease. J Alzheimers Dis (2012) 0.86
Simultaneous GDNF and BDNF application leads to increased motoneuron survival and improved functional outcome in an experimental model for obstetric brachial plexus lesions. Plast Reconstr Surg (2002) 0.85
Lentiviral-mediated gene transfer to model triplet repeat disorders. Methods Mol Biol (2004) 0.85
Lentiviral vectors express chondroitinase ABC in cortical projections and promote sprouting of injured corticospinal axons. J Neurosci Methods (2011) 0.84
Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors. J Control Release (2003) 0.83
Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adrenoleukodystrophy mouse model. Ann Neurol (2009) 0.83
Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model. Neurobiol Aging (2012) 0.83
Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi. Methods Mol Biol (2009) 0.82
Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery. Mol Ther (2003) 0.81
Viral vectors, animal models and new therapies for Parkinson's disease. Parkinsonism Relat Disord (2008) 0.81
Metabolic correction in oligodendrocytes derived from metachromatic leukodystrophy mouse model by using encapsulated recombinant myoblasts. J Neurol Sci (2007) 0.81
Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts. Mol Ther (2002) 0.80
Astrocyte-neuron co-culture on microchips based on the model of SOD mutation to mimic ALS. Integr Biol (Camb) (2013) 0.80
Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with co-implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor. Brain Res Bull (2005) 0.79
Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia. Kidney Int (2002) 0.79
A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells. Biomaterials (2013) 0.78
Allogeneic beta-islet cells correct diabetes and resist immune rejection. Proc Natl Acad Sci U S A (2002) 0.78
Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation. Biomaterials (2014) 0.75